Divi Resorts is reinforcing its commitment to making Caribbean travel more accessible, flexible, and rewarding for today's ...

Divi's Laboratories reported Q3FY26 results with a PAT of ₹583 crore, slightly down from ₹589 crore year-over-year. Total ...

Divi Resorts is reinforcing its commitment to making Caribbean travel more accessible, flexible, and rewarding for today’s travelers by highlighting the advantages of booking directly through its ...

Management said operational metrics improved during the quarter despite near-term revenue softness and indicated that growth ...

Feb 11 (Reuters) - Indian contract drug manufacturer Divi's Laboratories reported third-quarter profit below estimates on Wednesday, as high raw material costs and a one-off charge due to changes in ...

This article first appeared on GuruFocus. Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q3 2026 earnings on Feb 11, 2026. The consensus estimate for Q3 2026 revenue is $25.96 billion, ...

Divi's Labs reported a weaker-than-expected set of headline numbers on Wednesday.

Analysts have tweaked share price targets and future outlook after some of these companies announced their December quarter ...

Jefferies appeared the most bullish on the counter, hiking the target price, while Morgan Stanley reduced the target price, ...

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the ...

The custom synthesis business is poised for sustained growth as Divi's continues with aggressive capacity expansion, adds the brokerage.